Company: CERO
Filing Date: 2025-11-20
Form Type: 424B3
Source: 0001213900-25-113117
Chunk: 38

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-11-20
Form: 424B3
Chunk 38
---
 the 5-day volume weighted average price of a share of Common
Stock. Trigger Events include customary terms related to exchange listing, registration rights, failure to deliver shares on conversion
or exercise of derivative instruments, or insolvency. Notwithstanding the Series A Conversion Price Floor, if the Series A Conversion
Price Floor is greater than 80% of the 5-day volume weighted average price of a share of Common Stock, then the Conversion Amount (as
defined in the Certificates of Designations) is increased by a multiplier resulting in the convertibility of the shares of Series A Preferred
Stock into the number of shares of Common Stock that would have been issuable if the Alternate Conversion Price had been equal to such
lower volume weighted average price. Such multiplier was in effect from when the registration statement for the resale of shares of Common
Stock issuable upon conversion of the Series A Preferred Stock was declared effective on July 5, 2024 because such effectiveness was after
the applicable deadline therefore and, as a result of such multiplier, such registration statement registered fewer than the maximum number
of shares of Common Stock issuable upon such conversion. Such multiplier ceased to apply on January 6, 2025, the 20 trading
day after the effectiveness of the additional registration statement registering the resale of additional shares of Common Stock issuable
upon conversion of the Series A Preferred Stock resulting from such shortfall, which additional registration statement was declared effective
on December 5, 2024.

Redemptions: Upon
bankruptcy or liquidation, Series A Preferred Stock will be redeemed at a 25% premium (or at 50% premium 180 days after issuance) to the
greater of the conversion amount or the number of shares multiplied by the highest closing price within the preceding 20 days. Additionally,
the Company may voluntarily redeem the Series A Preferred Stock at a 20% premium to the greater of the conversion amount or the number
of shares multiplied by the highest closing price within the preceding 20 days.

<div align='center'>15</div>

The holders of the Series A Preferred Stock have
no voting rights.

In February 2024, the Company
consummated a private placement (the “Series A PIPE Financing”) of 10,089 shares of Series A Preferred Stock, warrants to
purchase 306 shares of Common Stock (the “February 2024 PIPE Common Warrants”) and warrants to purchase 2,500 shares of Series
A Preferred Stock (the “Preferred Warrants”) (